Managing Toxicity in Later-Line HER2+ mBC Treatments: Real-World Insights and Mitigation Strategies for Optimal Patient QOLs

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.